• Media
    • Press Releases
    • Archives
    • Media Inquiries
    • In the News
  • Join Us
    • Overview
    • Life at Tris
    • Our Culture
    • Diversity & Belonging
    • Current Opportunities
  • Connect
    • Contact Us
    • Join our Mailing List
Tris PharmaTris Pharma
  • Who We Are
    • Tris at a Glance
    • Leadership
    • Scientific Advisors
    • Patient Advocacy
    • Partnerships
    • Our Culture
    • Diversity & Belonging
    • Sustainability
    • Compliance
  • Medicines
  • Innovation
    • Overview
    • ADHD
    • Pain
    • Addiction
    • Technologies
  • Pipeline
    • Overview
    • ADHD Pipeline
    • Pain Pipeline
    • Other CNS Disorders
    • Clinical Publications
  • Who We Are
    • Tris at a Glance
    • Leadership
    • Scientific Advisors
    • Patient Advocacy
    • Partnerships
    • Our Culture
    • Diversity & Belonging
    • Sustainability
    • Compliance
  • Medicines
  • Innovation
    • Overview
    • ADHD
    • Pain
    • Addiction
    • Technologies
  • Pipeline
    • Overview
    • ADHD Pipeline
    • Pain Pipeline
    • Other CNS Disorders
    • Clinical Publications
  • Media
    • Press Releases
    • Archives
    • Media Inquiries
    • In the News
  • Join Us
    • Overview
    • Life at Tris
    • Our Culture
    • Diversity & Belonging
    • Current Opportunities
  • Connect
    • Contact Us
    • Join our Mailing List

Media

  • Press Releases
  • Archives
  • Media Inquiries
  • In the News

Press Releases

FEATURED PRESS RELEASE

September 1, 2026

Tris Pharma to Showcase ADHD Leadership and Commitment to Individualized Care at Fall 2026 Medical Conferences

September 3, 2026

Adneuris Therapeutics to Present at PAINWeek 2026

August 12, 2026

Tris Pharma Expands Support for People Living with ADHD Through New Partnerships with Calm Health and ADHD Central

August 5, 2026

Adneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Korea

July 14, 2026

Adneuris Therapeutics Grants Exclusive License to Zhejiang Conba Pharmaceutical to Advance Cebranopadol in Greater China
  • Who We Are
    • Tris at a Glance
    • Leadership
    • Scientific Advisors
    • Patient Advocacy
    • Partnerships
    • Our Culture
    • Diversity & Belonging
    • Sustainability
    • Compliance
  • Medicines
    • ADHD Products
  • Innovation
    • Overview
    • ADHD
    • Pain
    • Addiction
    • Technologies
  • Pipeline
    • Overview
    • ADHD Pipeline
    • Pain Pipeline
    • Other CNS Disorders
    • Clinical Publications
  • Join Us
    • Overview
    • Life at Tris
    • Our Culture
    • Diversity & Belonging
    • Current Opportunities
  • Media
    • Press Releases
    • Archives
    • Media Inquiries
    • In the News
  • Connect
    • Contact Us
    • Join our Mailing List
Tris 25 year anniversary logo
  • Who We Are
  • ADHD Products
  • Innovation
  • Pipeline
  • Media
  • Join Us
  • Connect

Tris Pharma logo

LinkedIn

instagram

twitter

facebook

Tris Pharma, Inc.
2031 US Highway 130
Monmouth Junction, NJ 08852

Telephone: (732) 940-2800

  • Privacy Policy
  • Terms and Conditions
  • Financial Conflict of Interest
  • Social
  • Cookies
  • Accessibility Statement

© Copyright 2026 Tris Pharma, Inc.